Inhaltsbereich
| 294 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 › » |
Seite 1 / 15
 Druckansicht
|
| Activity of T-DM1 in Her2-positive breast cancer brain metastases. |
| Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M |
| Clinical & experimental metastasis. 2015 Aug 25. doi: 10.1007/s10585-015-9740-3 |
| PMID: 26303828 |
| Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. |
| Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS |
| BMC medical genomics. 2015 Aug 22. doi: 10.1186/s12920-015-0129-6. pii: 10.1186/s12920-015-0129-6. pmc: PMC4546262 |
| PMID: 26297356 |
| Bevacizumab: no comeback in early breast cancer? |
| Bartsch R, Gnant M, Steger GG |
| The Lancet. Oncology. 2015 Aug 10. pii: S1470-2045(15)00124-2. doi: 10.1016/S1470-2045(15)00124-2 |
| PMID: 26272771 |
| Targeting bone microenvironment: Clinical implications. |
| Gnant M |
| Breast (Edinburgh, Scotland). 2015 Jul 31. pii: S0960-9776(15)00150-2. doi: 10.1016/j.breast.2015.07.012 |
| PMID: 26238438 |
| St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. |
| Gnant M, Thomssen C, Harbeck N |
| Breast care (Basel, Switzerland). 2015 Jul 21. doi: 10.1159/000430488. pii: brc-0010-0124. pmc: PMC4464099 |
| PMID: 26195941 |
| Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. |
| Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R |
| Clinical breast cancer. 2015 Jun 18. pii: S1526-8209(15)00123-8. doi: 10.1016/j.clbc.2015.06.007 |
| PMID: 26195436 |
| Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. |
| Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J |
| European journal of cancer (Oxford, England : 1990). 2015 Jun 11. pii: S0959-8049(15)00285-3. doi: 10.1016/j.ejca.2015.03.018 |
| PMID: 26074397 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. |
| Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 May 4. pii: mdv221. doi: 10.1093/annonc/mdv221. pmc: PMC4511219 |
| PMID: 25939896 |
| Reply to the letter to the editor 'Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients' by Fouad et al. |
| Gnant M, Dubsky PC |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 May 4. pii: mdv218. doi: 10.1093/annonc/mdv218 |
| PMID: 25939895 |
| Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. |
| Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 May 1. pii: mdv215. doi: 10.1093/annonc/mdv215 |
| PMID: 25935792 |
| The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. |
| Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M |
| British journal of cancer. 2015 Mar 24. pii: bjc201598. doi: 10.1038/bjc.2015.98. pmc: PMC4402462 |
| PMID: 25867274 |
| Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. |
| Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R |
| Breast care (Basel, Switzerland). 2015 Mar 11. doi: 10.1159/000368330. pii: brc-0009-0344. pmc: PMC4322687 |
| PMID: 25759615 |
| CDK4/6 inhibitors in luminal breast cancer. |
| Gnant M, Steger GG, Bartsch R |
| The Lancet. Oncology. 2014 Dec 16. pii: S1470-2045(14)71188-X. doi: 10.1016/S1470-2045(14)71188-X |
| PMID: 25524801 |
| Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. |
| Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Nov 17. pii: mdu544. doi: 10.1093/annonc/mdu544 |
| PMID: 25403582 |
| Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. |
| Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J |
| Anticancer research. 2014 Nov 4. pii: 34/11/6767 |
| PMID: 25368289 |
| Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. |
| Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Oct 20. pii: JCO.2014.55.6894. doi: 10.1200/JCO.2014.55.6894 |
| PMID: 25332252 |
| Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
| Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep 17. pii: mdu456. doi: 10.1093/annonc/mdu456 |
| PMID: 25231953 |
| Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. |
| Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P |
| Breast (Edinburgh, Scotland). 2014 Jul 10. pii: S0960-9776(14)00124-6. doi: 10.1016/j.breast.2014.06.011 |
| PMID: 25017122 |
| The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer. |
| Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P |
| British journal of cancer. 2014 Jul 8. pii: bjc2014339. doi: 10.1038/bjc.2014.339. pmc: PMC4150264 |
| PMID: 25003667 |
| 294 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 › » |
Seite 1 / 15
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
